Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Jason C Martin"'
Autor:
Kevin L. Russell, Richard E. Rupp, Javier O. Morales-Ramirez, Clemente Diaz-Perez, Charles P. Andrews, Andrew W. Lee, Tyler S. Finn, Kara S. Cox, Amy Falk Russell, Margaret M. Schaller, Jason C. Martin, Donna M. Hyatt, Sabrina Gozlan-Kelner, Androniki Bili, Beth-Ann G. Coller
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
Dengue (DENV) is a mosquito-borne virus with four serotypes causing substantial morbidity in tropical and subtropical areas worldwide. V181 is an investigational, live, attenuated, quadrivalent dengue vaccine. In this phase 1 double-blind, placebo-co
Externí odkaz:
https://doaj.org/article/48a11da47b0347aeb48e341a669a7e87
Autor:
Ulrike K. Buchwald, Charles P. Andrews, John Ervin, James T. Peterson, Gretchen M. Tamms, David Krupa, Patrick Ajiboye, Lucy Roalfe, Andrea L. Krick, Tina M. Sterling, Meihua Wang, Jason C. Martin, Jon E. Stek, Melvin A. Kohn, Temitope Folaranmi, Chitrananda Abeygunawardana, Jonathan Hartzel, Luwy K. Musey, the V110–029 Study Group
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 8, Pp 2678-2690 (2021)
In most countries worldwide, pneumococcal conjugate vaccines have been included in the infant immunization program, resulting in a significant reduction in the burden of pneumococcal disease in children and adults. Shifting serotype distribution due
Externí odkaz:
https://doaj.org/article/30752f92ec314a7fbfcbcdcdba1371a0
Autor:
Chitrananda Abeygunawardana, Jon E. Stek, Lucy Roalfe, Andrea Likos Krick, Tina M. Sterling, John Ervin, David Krupa, Meihua Wang, Charles P. Andrews, Temitope Folaranmi, Ulrike K. Buchwald, Jonathan Hartzel, Melvin A Kohn, Luwy Musey, Gretchen M. Tamms, Patrick Ajiboye, James T. Peterson, Jason C. Martin
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
In most countries worldwide, pneumococcal conjugate vaccines have been included in the infant immunization program, resulting in a significant reduction in the burden of pneumococcal disease in children and adults. Shifting serotype distribution due
Autor:
Jason C. Martin, Matthew T. Onorato, Beth-Ann Coller, Kenneth Liu, Rituparna Das, V Study Team, Rick Nichols, Scott A. Halperin, Rebecca J. Grant-Klein, Jakub K. Simon, Frans A. Helmond
Publikováno v:
The Journal of Infectious Diseases
Background This double-blind study assessed immunogenicity, lot consistency, and safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP). Methods Healthy adults (N = 1197) were randomized 2:
Autor:
Kevin Russell, Richard E Rupp, Javier O Morales-Ramirez, Clemente Diaz-Perez, Charles P Andrews, Andrew W Lee, Tyler S Finn, Kara Cox, Amy Falk Russell, Margaret M Schaller, Jason C Martin, Donna M Hyatt, Sabrina Gozlan-Kelner, Androniki Bili, Beth-Ann Coller
Publikováno v:
Open Forum Infectious Diseases
Background Dengue (DENV) is a mosquito-borne virus with four serotypes causing substantial morbidity in tropical and subtropical areas worldwide. A dengue vaccine that can be given to both seronegative and seropositive populations remains an importan
Autor:
Jon E. Stek, Jakub K. Simon, Jason C. Martin, Michelle G. Goveia, Stephanie O. Klopfer, Maria Petrecz
Publikováno v:
Vaccine. 39(20)
VAQTA™ (Hepatitis A Vaccine, inactivated [HAVi]; Merck & Co., Inc., Kenilworth, NJ, USA) is currently licensed for prevention of disease caused by hepatitis A virus in persons ≥12 months of age. This report summarizes statistical models developed
Autor:
Beth D. Kirkpatrick, Melissa Cook, Michele Sausser, Beulah P. Sabundayo, Liman Wang, Stephen S. Whitehead, Helen He, Anna P. Durbin, Donna Hyatt, Kristen K. Pierce, Jeffrey R. Sachs, Beth Ann Coller, Amy Falk Russell, Andrew W. Lee, Jason C. Martin, Palmtama L. Grier
Publikováno v:
Am J Trop Med Hyg
New dengue vaccines are needed to prevent this globally expanding vector-borne disease. The V180 vaccine candidate consists of four recombinant, soluble, dengue virus envelope glycoproteins and has been previously evaluated in two clinical trials for
Autor:
Myron J. Levin, Adriana Tovar Salazar, Lei Pang, Jennifer Canniff, Barbara J. McCarson, Kenneth E. Schmader, Yupanqui Caldas, Zoran Popmihajlov, Adriana Weinberg, Michael J Johnson, Jason C. Martin
Publikováno v:
The Journal of Infectious Diseases. 219:335-338
Protection against zoster conferred by zoster vaccine live (ZVL; Zostavax) wanes over time. We compared varicella-zoster virus cell-mediated immunity (VZV-CMI) of adults ≥70 years who received a second dose of ZVL ≥10 years after the initial dose
Autor:
Martin A. Croce, Taylor C. Stavely, Lt Jason C Martin, Joe E Holley, Nathan R. Manley, Peter E. Fischer
Publikováno v:
The American Surgeon. 85:123-125
Autor:
Nathan R, Manley, Joe E, Holley, Lt Jason C, Martin, Taylor C, Stavely, Martin A, Croce, Peter E, Fischer
Publikováno v:
The American surgeon. 85(3)